Amlitelimab, Sanofi’s Anti-OX40L Antibody, Hits All Primary and Key Secondary Endpoints in Phase 3 AD Trial September 4, 2025
AD Pipeline Watch: First Patient Enrolled in Phase 2b Trial of Evommune’s Oral MRGPRX2 Antagonist August 28, 2025
